Simian retrovirus receptor and neutralization mechanism by antibodies to the envelope glycoprotein.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Simian retrovirus receptor and neutralization mechanism by antibodies to the envelope glycoprotein.

Viral Immunol. 1999;12(1):47-56. Unique Identifier : AIDSLINE MED/99264037
Anderson DE; Torres JV; Department of Medical Microbiology and Immunology, School of; Medicine, University of California, Davis 95616, USA.

Abstract: Type D simian retroviruses (SRV) cause an acquired immunodeficiency syndrome (AIDS) in monkeys. Results of infection with SRV range from complete recovery with absence of viremia to a viremic state, which produces AIDS-like symptoms and culminates in death. These varied outcomes render the interaction of the host and SRV an attractive model for the study of immunosuppressive retrovirus resulting in different pathologic consequences. We describe here the isolation and determination of the molecular weight of the receptor for SRV. We demonstrate that a cell receptor with the same molecular weight is bound by the envelope protein of all five serotypes of SRV. We also show that the receptor recognizes a region containing amino acids 142-167 of the envelope protein of SRV serotype 1 (SRV-1). In addition, we show that a different region of SRV serotype 2 (SRV-2) envelope protein containing amino acids 93-106, interacts with a cell receptor of identical molecular weight. Furthermore, polyclonal and monoclonal antibodies that are directed to envelope epitopes 142-167 of SRV-1 or to 93-106 of SRV-2, specifically neutralize only the respective viral serotype. Our results indicate that the neutralization of SRV infectivity by antibodies is achieved through blocking the interaction between the virus and its cell receptor.

Keywords: JOURNAL ARTICLE Antibodies, Viral/*METABOLISM/PHARMACOLOGY B-Lymphocytes/CHEMISTRY/VIROLOGY Binding Sites, Antibody Cell Line Dose-Response Relationship, Immunologic Human Immunodominant Epitopes/IMMUNOLOGY Neutralization Tests/METHODS Peptides/IMMUNOLOGY Receptors, Virus/ANTAGONISTS & INHIB/*IMMUNOLOGY/ISOLATION & PURIF Retroviruses Type D, Simian/*IMMUNOLOGY Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Viral Envelope Proteins/CHEMISTRY/*IMMUNOLOGY
990930
A9991374

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .